Predicting Cardiovascular Risk in Participants Treated With Tirzepatide in the SURPASS 1-5 Trials

被引：0
|
作者：
Wiese, Russell J.
Wang, Hui
Mody, Reema
Benneyworth, Brian D.
机构：
来源：
CIRCULATION | 2023年 / 148卷
关键词：
Diabetes (Type II); Cardiovascular Risk; Drugs; Prediction model; Clinical trials;
D O I：
10.1161/circ.148.suppl_1.16589
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A16589
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Tirzepatide induces weight loss in patients with type 2 diabetes regardless of baseline BMI: a post hoc analysis of SURPASS-1 through SURPASS-5 studies
    Wilding, J. P. H.
    Kwan, A. Y. M.
    Maldonado, J. M.
    Wang, H.
    Rasouli, N.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S289 - S289
  • [32] Cardiovascular risk and atherosclerosis progression in hypertensive participants treated to blood pressure targets
    Gronewold, J.
    Kropp, R.
    Scharf, A. -C.
    Lehmann, N.
    Stang, A.
    Mahabadi, A. A.
    Kaelsch, H.
    Berger, K.
    Weimar, C.
    Dichgans, M.
    Budde, T.
    Moebus, S.
    Kleinschnitz, C.
    Joeckel, K. -H.
    Erbel, R.
    Hermann, D. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 332 - 332
  • [33] Machine learning for predicting the risk stratification of 1-5 cm gastric gastrointestinal stromal tumors based on CT
    Zhang, Cui
    Wang, Jian
    Yang, Yang
    Dai, Bailing
    Xu, Zhihua
    Zhu, Fangmei
    Yu, Huajun
    BMC MEDICAL IMAGING, 2023, 23 (01)
  • [34] PROs in Tirzepatide-Treated Adults with Type 2 Diabetes in SURPASS-1 to-6 by Age, Gender, BMI, and Weight Loss
    Boye, Kristina
    Thieu, Vivian
    Dong, Wenxiu
    Williamson, Suzanne E.
    Sapin, Helene
    DIABETES, 2024, 73
  • [35] Safety and efficacy of tirzepatide for SURPASS-2 through-5 participants ≥65 years old with BMI <30 kg/m2: a post hoc analysis
    Wilding, J.
    Rasouli, N.
    Kwan, A.
    Paik, J.
    Liu, M.
    Peleshok, J.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S333 - S334
  • [36] Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months
    Garg, Satish K.
    Kaur, Gurleen
    Renner, Drew
    Lanning, Monica S.
    Mason, Emma
    Beatson, Christie
    Ciesco, Kelly
    Snell-Bergeon, Janet
    DIABETES TECHNOLOGY & THERAPEUTICS, 2025, 27 (03) : 152 - 160
  • [37] Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4
    Malecki, Maciej T.
    Batterham, Rachel L.
    Sattar, Naveed
    Levine, Joshua A.
    Rodriguez, Angel
    Bergman, Brandon K.
    Wang, Hui
    Ghimpeteanu, Gabriela
    Lee, Clare J.
    DIABETES CARE, 2023, 46 (12) : 2292 - 2299
  • [38] Superior glycaemic control with semaglutide across SUSTAIN 1-5 clinical trials
    Ahmann, A.
    Chow, F.
    Fonseca, V.
    Mehta, R.
    Thomsen, H. F.
    Thielke, D.
    Petrie, J.
    DIABETOLOGIA, 2017, 60 : S377 - S377
  • [39] Tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in the management of type 2 diabetes: the SURPASS trials
    Aberle, Jens
    Forst, Thomas
    Heitmann, Elke
    Goergens, Sven W.
    Seufert, Jochen
    DIABETOLOGIE UND STOFFWECHSEL, 2023, 18 (06) : 461 - 474
  • [40] Post Hoc Analysis of SURPASS-1 to-5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
    De Block, Christophe
    Peleshok, Jennifer
    Wilding, John P. H.
    Kwan, Anita Y. M.
    Rasouli, Neda
    Maldonado, Juan M.
    Wysham, Carol
    Liu, Minzhi
    Aleppo, Grazia
    Benneyworth, Brian D.
    DIABETES THERAPY, 2025, 16 (01) : 43 - 71
12345